the AUC 3-7 by 59.6%.h (mean difference 26.9 (95% CI −3.8 to 57.6)).
during treatment with BAYx 1005 (mean in vivo. [7] [8] [9] Cysteinyl leukotrienes are released L8N 3Z5 difference 15.2 (95% confidence interval from human lungs after allergen challenge in A L Hamilton (CI) 9.4 to 21.00)) with a mean protection vitro, 10 while increases in cysteinyl leukotrienes as MK-886 18 and MK-0591, 19 have partially and urinalysis. With the exception of house dust mite, subjects were not currently exposed attenuated both the EAR and LAR, providing further direct evidence for a role of cysteinyl to allergens to which they were sensitised. Subjects had had no exacerbations of asthma and leukotrienes in the development of both these asthmatic responses.
no respiratory infections for at least four weeks before the start of the investigation. Baseline BAYx 1005 is an indirect leukotriene biosynthesis inhibitor which acts by binding to forced expiratory volume in one second (FEV 1 ) was >75% predicted normal 21 in all subjects 5-lipoxygenase activating protein (FLAP), an 18 kD leucocyte membrane protein necessary on all study days. All subjects were lifetime non-smokers. Women of child-bearing pofor the translocation and activation of 5-lipoxygenase. 5-Lipoxygenase is a pivotal enzyme tential were excluded from participation in the study. in the leukotriene biosynthetic pathway which binds to FLAP in the nuclear membrane to make a stable complex and subsequently converts arachidonic acid to 5-HPETE and then  
The study was performed in a double blind, to LTA 4 . LTA 4 is further converted to either LTB 4 or to the cysteinyl leukotrienes LTC 4 , placebo controlled manner with a crossover design. The study was divided into three LTD 4 and LTE 4 . BAYx 1005 antagonises the activity of FLAP, preventing the activation of 5-periods: a screening period (period l) and two treatment periods (periods 2 and 3). On all lipoxygenase and thereby inhibiting leukotriene synthesis. 20 study days subjects came to the laboratory having refrained from use of inhaled 2 agonists The purpose of the present study was to evaluate the effects of BAYx 1005 on the aller-for at least six hours and had not ingested caffeine-containing products on the morning gen-induced EAR and LAR and subsequent increase in airway responsiveness to metha-of each visit. Study periods were separated by at least two weeks. choline in atopic mildly asthmatic subjects.
Methods

Screening (period 1)
On day 1 of period 1 spirometric tests were  Nine subjects (seven men) were entered into performed to ensure subjects had an FEV 1 of >70% predicted. An allergen skin prick test the study; however, one subject had not demonstrated an allergen-induced LAR during was performed to determine atopic status, followed by a skin prick titration with doubling screening, which was a specific criterion for inclusion into the study, and was excluded. dilutions of the allergen producing the greatest weal on the skin test. The allergen end point The remaining eight subjects (seven men) were included in the statistical analysis. The study from the titration was subsequently used to calculate the starting concentration for the was approved by the hospital ethics committees and each subject gave written informed consent allergen inhalation challenge.
On day 2 a diluent control inhalation chalbefore beginning the study. All subjects were studied in the asthma research laboratory at lenge was performed and FEV 1 was followed for seven hours after the challenge. At the McMaster University Medical Centre. Relevant characteristics of the subjects are shown completion of the diluent inhalation challenge a methacholine inhalation challenge was perin table 1. All subjects had a history of mild stable asthma and documentation of asthma formed to determine the concentration of methacholine which caused fall in FEV 1 of 20% exacerbations induced by environmental allergen(s). Subjects were only using inhaled 2 (PC 20 ). The end point of the allergen skin prick titration and the methacholine PC 20 were used agonists to treat their asthma on an intermittent basis. Other than a clinical diagnosis of asthma, to estimate the PC 20 of the inhaled allergen extract using the formula described by Cockall subjects were healthy based on medical history, physical examination, electrocardio-croft et al. 22 Day 3 took place at least 24 hours after graphy, chest radiography, and laboratory screening for haematology, blood chemistry day 2. An allergen inhalation challenge was group.bmj.com on January 28, 2018 -Published by http://thorax.bmj.com/ Downloaded from performed to document the presence of an semilogarithmic non-cumulative scale. Solutions of methacholine chloride were stored early and late asthmatic response to the inhaled allergen, the starting concentration of allergen at 4°C and administered at room temperature. extract for inhalation was two doubling concentrations below the estimated allergen PC 20 . On day 4 a methacholine inhalation challenge Allergen and diluent inhalation challenges Allergen inhalation challenges were performed was performed, 30 hours after the allergen inhalation challenge, to document changes in as previously described 1 using a Wright nebuliser operated by oxygen at 50 psi and at a airway responsiveness following allergen inhalation.
flow rate that gave an output of 0.13 ml/min. FEV 1 was measured using a water sealed spirThe following specific criteria were used for entry into the treatment period of the study: ometer, with triplicate FEV 1 measurements at baseline and single FEV 1 measurements after (1) a methacholine PC 20 of <32 mg/ml on day 2 of period 1, (2) a documented allergen-allergen inhalation; volumes were recorded at body temperature, atmospheric pressure, satinduced EAR (defined as a fall in FEV 1 of >15% 0-3 hours after allergen inhalation) and urated with water vapour. For the screening allergen challenge in period 1 doubling conallergen-induced LAR (defined as a fall in FEV 1 of >15% 3-7 hours after allergen inhalation), centrations of allergen were inhaled by tidal breathing (nose clipped) for two minutes, with (3) allergen-induced airway hyperresponsiveness at 30 hours after allergen inhalation FEV 1 measured 10 minutes after each inhalation; inhalations were stopped when the FEV 1 (defined as >1 doubling dose decrease in methacholine PC 20 compared with the metha-had fallen by at least 15% from baseline. FEV 1 was subsequently measured at 20, 30, 45, 60, choline PC 20 on day 2 of period 1).
90 and 120 minutes and at hourly intervals up to seven hours after allergen inhalation. During the treatment periods (periods 2 and 3) only Treatment periods (periods 2 and 3) Subjects completed two treatment periods, one the three highest concentrations of allergen used in period 1 were inhaled. House dust with BAYx 1005 and one with matching placebo. Subjects were entered into the treat-extracts were obtained from Miles/HollisterStier, Mississagua, Ontario, and ragweed and ment sequence according to a randomised schedule. Each period consisted of five con-cat dander extracts were obtained from Dr Jerry Dolovich, Hamilton, Ontario. Allergen secutive days. On day 1 a methacholine inhalation challenge was performed; since the airway extracts from the same batch were used during the screening and both treatment periods for response to inhaled allergen is, in part, determined by the level of airway responsiveness, each subject. They were stored at −70°C and diluted in phosphate buffered saline with 1.5% each treatment period was started only when the methacholine PC 20 had returned to within benzyl alcohol for skin tests and allergen inhalation on the day of use. The diluent inhalation a single doubling concentration of the value determined at day 2 of period 1. Subjects began challenge was performed in the same manner as the allergen inhalation challenge, with subjects administration of medication on the morning of the following day (day 2). BAYx 1005 inhaling diluent (three inhalations of two minutes) instead of allergen. (2×250 mg) or matching placebo were administered orally twice daily (08.00 and 20.00 hours) on days 2, 3, and 4 and on the morning of day 5. On day 3 a methacholine inhalation      BAY 1005 challenge was performed. On day 4 an allergen inhalation challenge was performed two hours On day 4 of periods 2 and 3 (allergen inhalation challenge days) blood samples were obtained after administration of the morning dose of medication. On day 5 a methacholine challenge prior to administration of medication and at two, four, and six hours after administration was performed 30 hours after allergen inhalation.
for measurement of plasma levels of BAYx 1005.
 
Methacholine inhalation challenge    Airways responses to inhaled allergen were exMethacholine inhalation challenges were performed according to the method of Cockcroft pressed as the percentage fall in FEV 1 from the pre-allergen baseline value and plotted against et al. 23 Subjects inhaled saline followed by increasing doubling concentrations of metha-time. In addition, for each subject the maximal percentage decrease in FEV 1 from baseline durcholine chloride using a Wright nebuliser (output 0.13-0.15 ml/min; mass median aero-ing the EAR and LAR was recorded, and the trapezoidal area under the curve of the perdynamic diameter of particles=1.3 m). The nose was clipped and aerosols were inhaled centage change in FEV 1 versus time for the EAR (AUC 0-3 ) and the LAR (AUC 3-7 ) was through a mouthpiece during tidal breathing for two minutes. FEV 1 was measured using a calculated.
The method of Hills and Armitage 24 for anawater sealed spirometer (Warren E Collins Inc). The test was continued until a 20% fall in lysis of a two period crossover study was used to compare (1) the maximal percentage de-FEV 1 from the post-saline baseline value was obtained. The PC 20 was interpolated from in-crease in FEV 1 from baseline during the EAR, (2) the maximal percentage decrease in FEV 1 dividual dose-response curves drawn on a
Results
There was no significant difference in baseline FEV 1 before allergen between treatment periods, the FEV 1 being 3.81 (0.22) l during BAYx 1005 treatment and 3.63 (0.24) l during placebo treatment. The mean percentage fall in FEV 1 from baseline up to seven hours after allergen inhalation during the BAYx 1005 and placebo treatment periods is shown in fig 1. The p=0.03). The AUC 0-3 was also significantly reduced after treatment with BAYx 1005 compared with placebo ( 20 (1.61) mg/ml before and 2.87 (1.60) mg/ml (30 hours after allergen inhalation) −log PC 20 30 hours after allergen). However, despite a (24 hours before allergen inhalation)) using the significant allergen-induced decrease in methamethod of Hills and Armitage 24 for analysis of choline PC 20 of 1.7 doubling dilutions during a two period crossover study (n=6); a negative the screening period, allergen inhalation did not difference signified an increase in airway recause a significant change in the methacholine sponsiveness. Two subjects had to be excluded PC 20 during treatment with placebo (methafrom this analysis, one who did not take the final choline PC 20 2.67 (1.60) mg/ml 24 hours before two doses of medication during both treatment and 1.35 (1.56) mg/ml 30 hours after allergen). periods and a second who had a protocol vioThus, the change in logPC 20 from 24 hours lation during the screening period and did not before allergen to 30 hours after allergen was demonstrate allergen-induced airway hypernot significantly different between BAYx 1005 responsiveness. Probability values of <0.05, and placebo treatments (table 2) . two tailed, were considered statistically sigOn the day of the allergen challenge, after nificant. In all analyses tests for period and two days of treatment with BAYx 1005, the carryover effects were performed and no sigplasma concentrations of BAYx 1005 were 6.68 nificant effects were observed.
(1.41), 9.36 (1.14), 9.85 (1.13), and 9.98 (2.59) g/ml before and two, four, and six hours after the morning dose of BAYx 1005. BAYx 1005 was well tolerated in all subjects.
No clinically significant changes in physical There is now considerable evidence available may be considered to be a FLAP antagonist. BAYx 1005 has been shown to block IgE to suggest that leukotrienes may have a role in the pathogenesis of bronchial asthma. Leuko-mediated contractions of human airways pretreated with atropine, indomethacin, and chlortrienes are produced by both constitutive cells (mast cells, alveolar macrophages) and by pheniramine with a 10 times greater potency than MK-886; it also prevented the increase in infiltrating cells (eosinophils) within the lungs. 10 Urinary levels of LTE 4 12 13 and levels LTE 4 levels that was observed during the antiIgE challenge. 33 BAYx 1005 has also been of cysteinyl leukotrienes in BAL fluid 11 are increased following allergen challenge. Cy-shown to be effective in preclinical in vivo models of acute inflammation. In an arachidonic steinyl leukotrienes are potent contractile agonists for bronchial smooth muscle in vitro 5 6 and acid evoked mouse ear inflammation test BAYx 1005 was both topically (ED 50 18 g/ear) and aerosolised cysteinyl leukotrienes induce potent bronchoconstriction in both normal and asth-systemically (ED 50 48.7 mg/kg orally) active in inhibiting oedema formation. 34 matic subjects in vivo. 7-9 Inhalation of cysteinyl leukotrienes also induces eosinophilia in the We may compare the results of the present study with other studies that have examined airways 25 26 and increases airway responsiveness to histamine in asthmatic subjects. 27 They are the effects of FLAP antagonists on allergeninduced airway responses. With regard to allerpotent stimulants of mucus glycoproteins from human airways in vitro, 15 enhance secretion of gen-induced EAR, treatment with BAYx 1005, administered at a dose of 500 mg twice daily mucus in canine trachea in vivo, 28 and cause vasoconstriction and increased vascular per-for three days, appears to have been more effective than treatment with MK-886 admeability in the airways of guinea pigs.
14 In addition, LTB 4 induces neutrophil chemotaxis ministered in two oral doses of 500 mg and 250 mg one hour before and two hours after and aggregation and neutrophil-endothelial cell adhesion, enhances microvascular per-allergen inhalation, 18 and comparable to treatment with MK-0591 administered in doses meability, and induces neutrophil degranulation and lysosomal enzyme release. 29 of 250 mg at 24, 12, and 1.5 hours before inhalation of allergen.
19 BAYx 1005, MK-886, Thus, as well as being suitable for mediation of the acute bronchoconstrictor response, there and MK-0591 inhibited the maximum percentage fall in FEV 1 during the EAR by 57.1%, is evidence to suggest a role for leukotrienes in the inflammatory process involved in the 28.7%, and 57.0%, respectively, and the AUC 0-3 by 86.5%, 58.4%, and 79.1%, redevelopment of the LAR.
First generation cysteinyl leukotriene re-spectively. Treatment with BAYx 1005 was more effectceptor antagonists (LY171 883, L649 923, L648 051) showed modest efficacy in attenu-ive than MK-886 during the LAR (3-7 hours after allergen), attenuating the maximum perating the allergen-induced EAR, but had little or no effect on the LAR. Second generation, centage fall in FEV 1 by 46.0% and the AUC [3] [4] [5] [6] [7] by 59.6% compared with inhibitions of 19.1% highly selective and potent cysteinyl leukotriene receptor antagonists (ICI 204 219, 16 in the maximum percentage fall in FEV 1 and 43.6% in the AUC 3-7 with MK-886. However, MK-571 17 ) have been more efficacious, attenuating the EAR by up to 80%, with more the reduced effectiveness of MK-886 during the LAR may be explained partly by the pharmodest but significant attenuation of the LAR (up to 50%). The new potent leukotriene bio-macokinetics of MK-886 which has a short half life of two hours. Subject withdrawals after six synthesis inhibitors offer a potential advantage over the cysteinyl leukotriene receptor ant-hours in the study reported by Diamant and colleagues makes it difficult to compare the agonists by inhibiting the biosynthesis of both cysteinyl leukotrienes and LTB 4 . Although Zi-effectiveness of BAYx 1005 and MK-0591 during the LAR in terms of maximum percentage leuton and ZD2138, selective 5-LO inhibitors, failed to inhibit allergen-induced airway re-fall in FEV 1 and AUC 3-7 . However, it does appear that MK-0591 and BAYx 1005 were sponses, 30 31 the potent FLAP antagonists MK-886 and MK-0591 significantly attenuated comparably effective with respect to the reduction in the mean percentage fall in FEV 1 at both the EAR and the LAR. 18 19 BAYx 1005 is a potent and selective quino-each time point from three to six hours; at six hours after allergen inhalation there was a line derived leukotriene synthesis inhibitor in in vitro systems, including human and rat reduction of approximately 50% in the mean percentage fall in FEV 1 with MK-0591 and a polymorphonuclear leucocytes. 20 32 In studies with human polymorphonuclear leucocytes 54% reduction in the mean percentage fall in FEV 1 with BAYx 1005. BAYx 1005 was found to be 800 times more potent in intact cells than in cell-free systems.
While the similarities in the extent that BAYx 1005 and MK-0591 inhibited the EAR and the The Kd for binding to the high affinity binding site (0.165, mol/l) was almost identical to the LAR (up to six hours after allergen) point to a similar degree of inhibition of leukotriene IC 50 value for inhibition of LTB 4 synthesis (0.22 mol/1) in calcium ionophore A23187-biosynthesis, we do not have any data concerning the degree of inhibition of leukotriene stimulated leucocytes. In addition, the IC 50 36 Studies using larger sample sizes are required to establish conclusively whether these allergen) and observed a 76% inhibition of excretion of urinary LTE 4 compared with potent biosynthesis inhibitors and cysteinyl leukotriene antagonists are, indeed, effective placebo in the first two hours after challenge. The mean plasma concentration of BAYx 1005 inhibitors of allergen-induced airway hyperresponsiveness. was 10.5 mg/l (range 5.3-19.8 mg/l) at four hours after treatment which compares with a In summary, the results of this study have shown that the leukotriene biosynthesis inmean concentration of 9.85 mg/l (range 4.4-14.4 mg/l) at the same time point in our hibitor BAYx 1005 partially attenuates both allergen-induced EAR and LAR, adding further study.
If LTB 4 plays a significant part in the patho-support to the hypothesis that leukotrienes are important mediators in both the early and late physiology of allergen-induced asthma, then FLAP antagonists should provide an increased asthmatic responses after allergen inhalation in asthmatic subjects. protection compared with cysteinyl leukotriene receptor antagonists which block the actions of 
